| Literature DB >> 34815274 |
J M Ordóñez-Mena1,2, Thomas R Fanshawe3, Dona Foster4, Monique Andersson5, Sarah Oakley5, Nicole Stoesser2,4,5, A Sarah Walker2, Gail Hayward3.
Abstract
OBJECTIVES: To inform point-of-care test (POCT) development, we quantified the primary care demand for laboratory microbiology tests by describing their frequencies overall, frequencies of positives, most common organisms identified, temporal trends in testing and patterns of cotesting on the same and subsequent dates.Entities:
Keywords: epidemiology; microbiology; primary care
Mesh:
Year: 2021 PMID: 34815274 PMCID: PMC8611454 DOI: 10.1136/bmjopen-2020-048527
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Frequency of microbiology tests requested by primary care surgeries in Oxfordshire between 2008 and 2018
| Test group | Tests | Test results | Patients | ||||
| N | % | Positive* | Mixed growth | Equivocal | N | %† | |
|
| 1 596 752 | 100 | 393 905 | 100 | |||
|
| |||||||
| Urine | 673 612 | 42.2 | 26.7 | 25.6 | 3.05 | 247 356 | 62.8 |
| Genital | 108 861 | 6.82 | 27.8 | – | – | 69 055 | 17.5 |
| Surface swab | 68 288 | 4.28 | 41.1 | – | – | 48 854 | 12.4 |
| Faecal | 68 240 | 4.27 | 9.74 | – | – | 55 032 | 14.0 |
| Antenatal urine | 57 423 | 3.60 | 6.57 | 25.4 | 1.79 | 37 923 | 9.63 |
| Dermatophyte | 24 093 | 1.51 | 26.8 | – | – | 21 029 | 5.34 |
| Pus | 4933 | 0.31 | 35.0 | 3.26 | – | 4332 | 1.10 |
| Respiratory tract | 3211 | 0.20 | 93.6 | – | – | 1671 | 0.42 |
|
|
| ||||||
| Hepatitis B | 116 366 | 7.29 | Surface antigen: | 80 658 | 20.5 | ||
| HIV | 99 436 | 6.23 | 0.56 | 67 467 | 17.1 | ||
| | 84 686 | 5.30 | 0.06 | 58 002 | 14.7 | ||
| | 76 711 | 4.80 | 2.35 | 55 682 | 14.1 | ||
| Rubella (antibody) | 76 556 | 4.79 | 96.5 | 51 705 | 13.1 | ||
| | 51 137 | 3.20 | 20.0 | 45 456 | 11.5 | ||
| Hepatitis C | 30 910 | 1.94 | Antibody: 5.52 (1633/29561) | 25 468 | 6.47 | ||
| | 22 422 | 1.40 | 2.45 | 19 076 | 4.84 | ||
| | 12 975 | 0.81 | 5.70 | 10 489 | 2.66 | ||
| Gastrointestinal bacterial panel‡ | 10 015 | 0.63 | 15.6 | 9202 | 2.34 | ||
| Epstein-Barr virus | 6877 | 0.43 | EBNA IgG: 70.5 (4649/6592) | 6570 | 1.67 | ||
*Positivity in cultures reflects the detection of one or more organisms in the specimen provided, and should not necessarily be interpreted as an indication of pathogenicity.
†Percentages may not add to total as patients could have more than a single test of a different type during the study period.
‡An enteric pathogen panel that tests for Shigella spp, Salmonella spp, Campylobacter spp and shiga toxin genes (for the detection of shigatoxigenic Escherichia coli such as O157).
EBNA, Epstein-Barr virus Nuclear Antigen; VCA, viral capsid antigen.
Frequency of microbiology tests by sex in Oxfordshire primary care practices between 2008 and 2018
| Test group | Male | Female | ||||||
| N tests | % | N patients | %* | N tests | % | N patients | %* | |
|
| 343 020 | 100 | 136 538 | 100 | 1 253 732 | 100 | 257 367 | 100 |
|
| ||||||||
| Urine | 171 656 | 50.0 | 75 460 | 55.3 | 501 956 | 40.0 | 171 896 | 66.8 |
| Genital | 648 | 0.19 | 600 | 0.44 | 108 213 | 8.63 | 68 455 | 26.6 |
| Surface swab | 28 966 | 8.44 | 20 511 | 15.0 | 39 322 | 3.14 | 28 343 | 11.0 |
| Faecal | 30 594 | 8.92 | 25 014 | 18.3 | 37 646 | 3.00 | 30 018 | 11.7 |
| Antenatal urine | – | – | – | – | 57 415 | – | 37 915 | – |
| Dermatophyte | 11 278 | 3.29 | 9862 | 7.22 | 12 815 | 1.02 | 11 167 | 4.34 |
| Pus | 2566 | 0.75 | 2234 | 1.64 | 2367 | 0.19 | 2098 | 0.82 |
| Respiratory tract | 1337 | 0.39 | 751 | 0.55 | 1874 | 0.15 | 920 | 0.36 |
|
| ||||||||
| Hepatitis B | 17 952 | 5.23 | 15 033 | 11.0 | 98 414 | 7.85 | 65 625 | 25.5 |
| HIV | 9418 | 2.75 | 7781 | 5.70 | 90 018 | 7.18 | 59 686 | 23.2 |
| | 1865 | 0.54 | 1739 | 1.27 | 82 821 | 6.61 | 56 263 | 21.9 |
| | 4655 | 1.36 | 4342 | 3.18 | 72 056 | 5.75 | 51 340 | 20.0 |
| Rubella | 353 | 0.10 | 342 | 0.25 | 76 203 | 6.08 | 51 363 | 20.0 |
| | 21 463 | 6.26 | 19 354 | 14.2 | 29 674 | 2.37 | 26 102 | 10.1 |
| Hepatitis C | 16 428 | 4.79 | 13 489 | 9.88 | 14 482 | 1.16 | 11 979 | 4.65 |
| | 11 571 | 3.37 | 9751 | 7.14 | 10 851 | 0.87 | 9325 | 3.62 |
| | 5033 | 1.47 | 4117 | 3.02 | 7942 | 0.63 | 6372 | 2.48 |
| Gastrointestinal bacterial panel† | 4486 | 1.31 | 4146 | 3.04 | 5529 | 0.44 | 5056 | 1.96 |
| Epstein-Barr virus | 2743 | 0.80 | 2639 | 1.93 | 4134 | 0.33 | 3931 | 1.53 |
*Note these percentages may not add to the total as patients could have more than a single test of a different type during the study period.
†An enteric pathogen panel that tests for Shigella spp, Salmonella spp, Campylobacter spp and shiga toxin genes (for the detection of shigatoxigenic Escherichia coli such as O157).
Figure 1Heat map showing the percentage of all tests in the row that were also accompanied by the test in the column.
Figure 2Heat map showing the percentage of all tests in the row that were followed by the test in the column within 7 days.
Frequency of the five most common organisms by test group in Oxfordshire primary care practices between 2008 and 2018
| Test group | N positive* | % of positive specimens | % of all tested specimens |
|
| 180 047 | 100 | 26.7 |
| | 132 227 | 73.4 | 19.6 |
| | 13 093 | 7.27 | 1.94 |
| | 7050 | 3.92 | 1.05 |
| | 6783 | 3.77 | 1.01 |
| | 6728 | 3.74 | 1.00 |
| Other | 14 177 | 7.87 | 2.10 |
|
| 30 270 | 100 | 27.8 |
| | 21 767 | 71.9 | 20.0 |
| Metronidazole-sensitive anaerobes | 5316 | 17.6 | 4.88 |
| | 4421 | 14.6 | 4.06 |
| | 676 | 2.23 | 0.62 |
| | 393 | 1.30 | 0.36 |
| Other | 41 | 0.14 | 0.04 |
|
| 28 029 | 100 | 41.0 |
| | 16 798 | 59.9 | 24.6 |
| | 8495 | 30.3 | 12.4 |
| | 3227 | 11.5 | 4.73 |
| Metronidazole-sensitive anaerobes | 1109 | 3.96 | 1.62 |
| | 1001 | 3.57 | 1.47 |
| Other | 797 | 2.84 | 1.17 |
|
| 6649 | 100 | 9.74 |
| | 5631 | 84.7 | 8.25 |
| | 608 | 9.14 | 0.89 |
| G | 288 | 4.33 | 0.42 |
| | 83 | 1.25 | 0.12 |
| | 82 | 1.23 | 0.12 |
| Other | 4 | 0.06 | 0.01 |
|
| 3773 | 100 | 6.57 |
| | 1796 | 47.6 | 3.13 |
| | 1250 | 33.1 | 2.18 |
| | 325 | 8.61 | 0.57 |
| | 193 | 5.12 | 0.34 |
| | 100 | 2.65 | 0.17 |
| Other | 109 | 2.89 | 0.19 |
|
| 6452 | 100 | 26.8 |
| | 5746 | 89.1 | 23.8 |
| | 577 | 8.94 | 2.39 |
| | 94 | 1.46 | 0.39 |
| | 68 | 1.05 | 0.28 |
| | 44 | 0.68 | 0.18 |
| Other | 8 | 0.12 | 0.03 |
|
| 1725 | 100 | 35.0 |
| | 1076 | 62.4 | 21.8 |
| | 295 | 17.1 | 5.98 |
| | 186 | 10.8 | 3.77 |
| | 123 | 7.13 | 2.49 |
| Metronidazole-sensitive anaerobes | 100 | 5.80 | 2.03 |
| Other | 218 | 12.6 | 4.42 |
|
| 3004 | 100 | 93.6 |
| | 1203 | 40.0 | 37.5 |
| | 880 | 29.3 | 27.4 |
| | 314 | 10.5 | 9.78 |
| | 306 | 10.2 | 9.53 |
| | 283 | 9.42 | 8.81 |
| Other | 358 | 11.9 | 11.1 |
*The number of tests positives for all organisms within a test group may not add up to the total number of positives, as some specimens may be positive for more than one organism.
†Predominantly Group B streptococcus.